Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study

Tanaka, Yoshiya; Hirata, Shintaro; Kubo, Satoshi; Fukuyo, Shunsuke; Hanami, Kentaro; Sawamukai, Norifumi; Nakano, Kazuhisa; Nakayamada, Shingo; Yamaoka, Kunihiro; Sawamura, Fusae; Saito, Kazuyoshi

doi:10.1136/annrheumdis-2013-204016

Public

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study

Published in Annals of the Rheumatic Diseases • Nov 29, 2013

Authors:

Yoshiya Tanaka

Shintaro Hirata

Satoshi Kubo

Abstract

OBJECTIVES: To investigate the possibility of discontinuing adalimumab (ADA) for 1 year without flaring (DAS28-erythrocyte sedimentation rate (ESR) ≥3.2), and to identify factors enabling established patients with rheumatoid arthritis (RA) to remain ADA-free. METHODS: Of 197 RA patients treated with...

Subject

Medicine

Surgery

Adalimumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!